1. Home
  2. ZKH vs STTK Comparison

ZKH vs STTK Comparison

Compare ZKH & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ZKH

ZKH Group Limited

HOLD

Current Price

$2.68

Market Cap

484.8M

Sector

N/A

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$6.62

Market Cap

538.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZKH
STTK
Founded
1998
2016
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
484.8M
538.3M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
ZKH
STTK
Price
$2.68
$6.62
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$10.00
AVG Volume (30 Days)
90.3K
1.6M
Earning Date
05-19-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
53.02
EPS
N/A
N/A
Revenue
N/A
$1,000,000.00
Revenue This Year
$9.02
N/A
Revenue Next Year
$10.41
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.92
$0.71
52 Week High
$3.90
$8.33

Technical Indicators

Market Signals
Indicator
ZKH
STTK
Relative Strength Index (RSI) 54.84 56.00
Support Level $2.47 $5.81
Resistance Level $3.09 $6.81
Average True Range (ATR) 0.23 0.64
MACD 0.05 0.12
Stochastic Oscillator 100.00 62.31

Price Performance

Historical Comparison
ZKH
STTK

About ZKH ZKH Group Limited

ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: